NinePoint Medical, Inc., an emerging leader in the development of medical devices for in vivo imaging, today announced that it has expanded its leadership team with the appointments of Judy Huber to chief financial officer and Kurt Heine to vice president of sales. In addition, FierceMedicalDevices today named NinePoint Medical to its inaugural “Fierce 15” list, designating it as one of the leading medical device and diagnostic companies of 2012.
“It is an honor to be among the innovative companies selected for FierceMedicalDevices’ first Fierce 15 list. This designation is a testament to the great work of the NinePoint Medical team and our potential to make a significant impact in both the lives of patients and the medical devices market,” said Charles S. Carignan, M.D., president and chief executive officer of NinePoint Medical. “We are also pleased to welcome Judy and Kurt to our leadership team. Their extensive financial and sales expertise will be invaluable as we prepare for the launch and commercialization of the NvisionVLE™ Imaging System in the U.S. and Europe next year.”
Enhanced Leadership Team
As chief financial officer, Ms. Huber brings to NinePoint Medical more than 25 years of financial experience, predominately in the medical device industry. Prior to joining NinePoint, Ms. Huber served as chief financial officer of ConforMIS, Inc., where she was an integral member of the leadership team that created the foundation for the operational and commercial strategy of the company’s patient-specific knee replacement systems. Prior to ConforMIS, Ms. Huber served as vice president and controller at NxStage Medical. In this role, she was instrumental in building the financial and administrative infrastructure that led to the company's initial public offering, secondary financing and acquisition of Medisystems Corporation. Ms. Huber also spent more than nine years in various financial positions with C.R. Bard through the acquisition by AVE/Medtronic, where she supported multiple divisions focused on improving the economic efficiencies in their manufacturing operations. Ms. Huber holds a B.S. in accounting from the State University of New York at Geneseo and an M.B.A. from Babson College.
As vice president of sales, Mr. Heine brings to NinePoint Medical nearly 15 years of sales and leadership experience in the endoscopy field. Prior to joining NinePoint, Mr. Heine held positions of increasing responsibility at Boston Scientific Corporation. For the past six years, he was a director of sales and a part of the senior sales management team, where his responsibilities included mentorship of Boston Scientific's international business, forecasting and sales execution of the U.S. business, and development of region and territory managers in the field. Prior to that, Mr. Heine served in region management and global sales training. He attended the U.S. Naval Academy and holds a B.S. in biology from Virginia Commonwealth University.
FierceMedicalDevices editors Mark Hollmer and Damian Garde, in conjunction with editor-in-chief John Carroll and executive editor Ryan McBride, chose this year’s winners based on their top management teams, notable financial backing and promising technologies and market opportunities. NinePoint Medical was chosen as one of the Fierce 15 based, in part, on its creativity and innovations in the industry.
“NinePoint’s imaging technology has the potential to bridge the gap between the time of initial imaging to diagnosis and treatment, saving time and money for patients in need,” said Garde.
An internationally recognized e-newsletter reaching more than 34,000 medical device and diagnostic industry professionals, FierceMedicalDevices provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on clinical studies, FDA/EMEA regulations, and post-marketing.
About NinePoint Medical, Inc.
NinePoint Medical, Inc. is a transformational medical device company developing innovative, real-time, in vivo imaging devices focused on dramatically improving patient care. Through its proprietary NvisionVLE™ Imaging System, NinePoint intends to bridge the gap between the time of initial imaging to diagnosis and treatment of disease. The NvisionVLE Imaging System will enable physicians and pathologists, for the first time, to view real-time, high-resolution, volumetric images of organs and tissues up to 3mm deep at better than 10 micron resolution. NinePoint is preparing for a commercial launch of the NvisionVLE Imaging System in the U.S. and Europe in 2013. Headquartered in Cambridge, Mass., NinePoint is backed by Third Rock Ventures and Prospect Venture Partners. For more information, please visit www.ninepointmedical.com.Business Wire
Last updated on: 02/10/2012
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.